|
|
|
||||
KGI alumna Nida Moosa (MBS '06), President Sheldon Schuster and alumnus Joshua Seno (MBS '02) at one of KGI's many alumni networking events.
The U.S. Food and Drug Administration and Keck Graduate Institute will host the first-ever workshop on developing Orphan Drug Applications on February 25-26, 2010. Under the guidance of Dr. Tim Coté, Director of the FDA’s Office of Orphan Product Development, and FDA staffers, attendees will create an application for orphan drug designation to be submitted to the FDA at the close of the workshop. Attendance is limited and is subject to approval by the FDA.
M. Ian Phillips, KGI's Norris Professor of Applied Life Sciences, has been named a Fellow by the American Association for the Advancement of Science (AAAS), an elite group of scientists that includes Nobel Prize winners and members of the National Academy of Sciences.
KGI educates future leaders of the bioscience industry through distinctive Professional Science Master's and PhD programs offering integrated life science/engineering/business curriculums and focusing on industry projects and collaborations. Degree programs include our Master of Bioscience (MBS), Postdoctoral Professional Masters in Bioscience Management (PPM) and Post Baccalaureate Premedical Certificate Program. For more information, click here.
Prof. Phillips Elected Fellow of AAAS
M. Ian Phillips, KGI's Norris Professor of Applied Life Sciences, has been named a Fellow by the American Association for the Advancement of Science (AAAS), an elite group of scientists that includes Nobel Prize winners and members of the National Academy of Sciences.
Orphan Drug Designation Workshop
The U.S. Food and Drug Administration and Keck Graduate Institute will host the first-ever workshop on developing Orphan Drug Applications on February 25-26, 2010. Under the guidance of Dr. Tim Coté, Director of the FDA’s Office of Orphan Product Development, and FDA staffers, attendees will create an application for orphan drug designation to be submitted to the FDA at the close of the workshop. Attendance is limited and is subject to approval by the FDA.
FDA Launches Orphan Drug Workshop at KGI
The U.S. Food and Drug Administration (FDA) has announced the launch of an orphan drug workshop series-an opportunity for biotechnology companies, pharmaceutical firms, academics and other interested parties to spend two days creating applications for orphan status designation, under the guidance of staff from FDA's Office of Orphan Products Development (OOPD). The first workshop is planned for Feb. 25-26, 2010, hosted by the Center for Rare Disease Therapies at Keck Graduate Institute (KGI) in Claremont, Calif.
February 10, 1:00 pm - 5:00 pm
KGI Talent Spotlight Day
February 16, 11:00 am - 12:00 pm
Industrial Strength Bio Seminar Series featuring Matthew Jenusaitis, President & CEO of OCTANe
FDA Orphan Drug Workshop